204 related articles for article (PubMed ID: 15717094)
21. Temporal lesions and widespread involvement of white matter associated with multi-organ inflammatory disease in human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Mendes GB; Kalil RS; Rosadas C; de Freitas MR; Puccioni-Sohler M
Int J Infect Dis; 2014 Aug; 25():1-3. PubMed ID: 24815740
[TBL] [Abstract][Full Text] [Related]
22. Presence of tropical spastic paraparesis/human T-cell lymphotropic virus type 1-associated myelopathy (TSP/HAM)-like among HIV-1-infected patients.
Casseb J; de Oliveira AC; Vergara MP; Montanheiro P; Bonasser F; Meilman Ferreira C; Smid J; Duarte AJ
J Med Virol; 2008 Mar; 80(3):392-8. PubMed ID: 18205234
[TBL] [Abstract][Full Text] [Related]
23. Programmed death-1 (PD-1)/PD-1 ligand pathway-mediated immune responses against human T-lymphotropic virus type 1 (HTLV-1) in HTLV-1-associated myelopathy/tropical spastic paraparesis and carriers with autoimmune disorders.
Kozako T; Yoshimitsu M; Akimoto M; White Y; Matsushita K; Soeda S; Shimeno H; Kubota R; Izumo S; Arima N
Hum Immunol; 2011 Nov; 72(11):1001-6. PubMed ID: 21851845
[TBL] [Abstract][Full Text] [Related]
24. Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)-Infected Individuals Without HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study.
Tanajura D; Castro N; Oliveira P; Neto A; Muniz A; Carvalho NB; Orge G; Santos S; Glesby MJ; Carvalho EM
Clin Infect Dis; 2015 Jul; 61(1):49-56. PubMed ID: 25820277
[TBL] [Abstract][Full Text] [Related]
25. Clustering of HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) and infective dermatitis associated with HTLV-1 (IDH) in Salvador, Bahia, Brazil.
da Silva JL; Primo JR; de Oliveira Mde F; Batista Eda S; Moreno-Carvalho O; Farré L; Bittencourt AL
J Clin Virol; 2013 Oct; 58(2):482-5. PubMed ID: 23932323
[TBL] [Abstract][Full Text] [Related]
26. Incidence of human T cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in a long-term prospective cohort study of initially asymptomatic individuals in Brazil.
Romanelli LC; Caramelli P; Martins ML; Gonçalves DU; Proietti FA; Ribas JG; Araújo MG; Carneiro-Proietti AB
AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1199-202. PubMed ID: 23617363
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of HTLV-1 HBZ and proviral load, together with host IFN λ3, in pathogenesis of HAM/TSP.
Mozhgani SH; Jaberi N; Rezaee SA; Bustani R; Jazayeri SM; Akbarin MM; Milani S; Tarokhian H; Norouzi M
J Med Virol; 2017 Jun; 89(6):1102-1107. PubMed ID: 27787900
[TBL] [Abstract][Full Text] [Related]
28. [Interstitial pneumonia in patients with human T-cell lymphotropic virus type-1 infection].
Sugimoto M
Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():36-41. PubMed ID: 8007471
[TBL] [Abstract][Full Text] [Related]
29. Dermatological findings of human T lymphotropic virus type 1 (HTLV-I)-associated myelopathy/tropical spastic paraparesis.
Lenzi ME; Cuzzi-Maya T; Oliveira AL; Andrada-Serpa MJ; Araújo AQ
Clin Infect Dis; 2003 Feb; 36(4):507-13. PubMed ID: 12567310
[TBL] [Abstract][Full Text] [Related]
30. An Update on the Global Epidemic of Human T-Cell Lymphotrophic Virus Type-I (HTLV-I).
Edlich R; Hill LG; Williams FM
J Long Term Eff Med Implants; 2017; 27(2-4):355-368. PubMed ID: 29773049
[TBL] [Abstract][Full Text] [Related]
31. HTLV-I, infective dermatitis, and tropical spastic paraparesis.
La Grenade L
Mol Neurobiol; 1994; 8(2-3):147-53. PubMed ID: 7999311
[TBL] [Abstract][Full Text] [Related]
32. HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV-I-infected Th1 cells in the pathogenesis, and therapeutic strategy.
Nakamura T
Folia Neuropathol; 2009; 47(2):182-94. PubMed ID: 19618340
[TBL] [Abstract][Full Text] [Related]
33. Human T-lymphotrophic virus type 1-associated infective dermatitis: a comprehensive review.
Lee R; Schwartz RA
J Am Acad Dermatol; 2011 Jan; 64(1):152-60. PubMed ID: 20691499
[TBL] [Abstract][Full Text] [Related]
34. Risk factors and cofactors for human T-cell lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Jamaica.
Krämer A; Maloney EM; Morgan OS; Rodgers-Johnson P; Manns A; Murphy EL; Larsen S; Cranston B; Murphy J; Benichou J
Am J Epidemiol; 1995 Dec; 142(11):1212-20. PubMed ID: 7485068
[TBL] [Abstract][Full Text] [Related]
35. Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls.
Silva MT; Mattos P; Alfano A; Araújo AQ
J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1085-9. PubMed ID: 12876239
[TBL] [Abstract][Full Text] [Related]
36. The human T-cell leukemia virus type 1 (HTLV-1): new insights into the clinical aspects and molecular pathogenesis of adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-associated myelopathy (TSP/HAM).
Shuh M; Beilke M
Microsc Res Tech; 2005 Nov; 68(3-4):176-96. PubMed ID: 16276549
[TBL] [Abstract][Full Text] [Related]
37. High IFN-γ/IL-10 expression ratio and increased frequency of persistent human T-cell lymphotropic virus type 1-infected clones are associated with human T-cell lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis development.
Espíndola OM; Oliveira LC; Ferreira PM; Leite AC; Lima MA; Andrada-Serpa MJ
Intervirology; 2015; 58(2):106-14. PubMed ID: 25833232
[TBL] [Abstract][Full Text] [Related]
38. Anti-HTLV antibody profiling reveals an antibody signature for HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP).
Burbelo PD; Meoli E; Leahy HP; Graham J; Yao K; Oh U; Janik JE; Mahieux R; Kashanchi F; Iadarola MJ; Jacobson S
Retrovirology; 2008 Oct; 5():96. PubMed ID: 18937847
[TBL] [Abstract][Full Text] [Related]
39. HTLV-I associated infective dermatitis may be an indolent HTLV-I associated lymphoma.
Gonçalves DU; Guedes AC; Carneiro-Proietti AB; Lambertucci JR
Braz J Infect Dis; 2000 Apr; 4(2):100-2. PubMed ID: 10797656
[TBL] [Abstract][Full Text] [Related]
40. Inflammatory manifestations of HTLV-1 and their therapeutic options.
Martin F; Taylor GP; Jacobson S
Expert Rev Clin Immunol; 2014 Nov; 10(11):1531-46. PubMed ID: 25340428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
